Emergence of nanomedicine as cancer targeted magic bullets: Recent development and need to address the toxicity apprehension

Current Drug Discovery Technologies

Volumn 9, Issue 4, 2012, Pages 319-329

  Rahman, Mahfoozur ^a   Ahmad, Mohammad Zaki ^a   Kazmi, Imran ^b   Akhter, Sohail ^c   Afzal, Muhammad ^b   Gupta, Gaurav ^b   Sinha, Vivek Ranjan ^d  

^a Dreamz College of Pharmacy   (India)

^b Siddhartha Institute of Pharmacy   (India)

^c HAMDARD UNIVERSITY   (India)

^d PANJAB UNIVERSITY   (India)

Author keywords

Clinical status of nanoparticles; Nanocarriers; Nanotechnology; Nanotoxicity

Indexed keywords

EID: 84868014640     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312803305898     Document Type: Article

References (101)

1. Ahmad MZ, Akhter S, Rahman M, et al. Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opin Drug Deliv 2010; 7(8): 927-42.
2. Akhter S, Ahmad MZ, Rahman M, et al. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des 2011; 17: 1834-50.
3. Rahman M, Ahmad MZ, Kazmi I, et al. Novel Approach for the Treatment of Cancer: Theranostic Nanomedicine . Pharmacologia 2012; 3(9): 371-6.
4. Rahman M, Ahmad MZ, Kazmi I, et al. Advancement in multifunctional nanoparticles for the effective treatment of cancer. Expert Opin Drug Deliv 2012; 9 : 367-81.
5. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008; 13: 30-7.
6. Hui EE, Bhatia SN. Micromechanical control of cell-cell interactions. Proc Natl Acad Sci USA 2007; 104: 5722-57.
7. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005; 65: 5317-24. (Pubitemid 40827344)
8. Sahoo SK, Parveen S, Panda JJ. T he present and future of nanotechnology in human health care. Nanomedicine 2007; 3: 20-31. (Pubitemid 46428187)
9. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8: 1112-20. (Pubitemid 37547917)
10. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. Faseb J 2005; 19 : 311-30. (Pubitemid 40316520)
11. Miao S, Hickey SG, Rellinghaus B, Waurisch C, Eychmüller A. Synthesis and characterization of cadmium phosphide quantum dots emitting in the visible red toz near-infrared. J A m Chem Soc 2010; 132: 5613-15.
12. Xie R, Chen K, Chen X, Peng X. In As/InP/ZnSe core/shell/shell quantum dots as near-infrared emitters: bright, narrow-band, noncadmium containing, and biocompatible. Nano Res 2008; 1: 457-64.
13. Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum dotaptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007; 7: 3065-70. (Pubitemid 350132931)
14. Yuan J, Guo W, Yang X, Wang E. Anticancer drug-DNA interactions measured using a photoinduced electron-transfer mechanism based on luminescent quantum dots. Anal Chem 2009; 81: 362-8.
15. Chen AA, Derfus AM, Khetani SR, Bhatia SN. Quantum dots to monitor RNA delivery and improve gene silencing. Nucleic Acids Res 2005; 33: e190. (Pubitemid 43125090)
16. Qi L, Gao X. Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano 2008; 2: 1403-10.
17. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007; 28(8) : 1565-71. (Pubitemid 46039833)
18. Zhang Y, So MK, Rao J. Protease-modulated cellular uptake of quantum dots. Nano Lett 2006; 6(9) : 1988-92. (Pubitemid 44555242)
19. Bonoiu A, Mahajan SD, Ye L, et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res 2009; 1282 :142-55.
20. Tsay JM, Trzoss M, Shi L, et al. Singlet oxygen production by peptide-coated quantum dot-photosensitizer conjugates. J A m Chem Soc 2007; 129 : 6865-71. (Pubitemid 46847529)
21. Xie J, Huang J, Li X, Sun S, Chen X. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 2009; 16: 1278-94.
22. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomedicine 2006; 1: 157-68.
23. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021 (Pubitemid 40044762)
24. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med 1998; 40(2): 236-42. (Pubitemid 28361526)
25. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents:physiochemical characteristics and application in MR imaging. Eur Radiol 2001; 11(11): 2319-31. (Pubitemid 33041104)
26. Hahn PF, Stark DD, Lewis JM, et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imagine. Radiology 1990; 175(3) : 695-700. (Pubitemid 20191929)
27. Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesion. Eur Radiol 1998; 8(7): 1198-4.
28. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002; 23: 1553-61. (Pubitemid 34158578)
29. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004; 11: 169-83. (Pubitemid 38720414)
30. Paciotti GF, Kingston DGI, Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Dev Res 2006; 67: 47-54. (Pubitemid 43765048)
31. Chen J, Saeki F, Wiley BJ, et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett 2005; 5: 473-7. (Pubitemid 40449718)
32. Link S, El-Sayed MA. Size and temperature dependence o f the Plasmon absorption of colloidal gold nanoparticles. J Phys Chem B 1999; 103: 4212-17. (Pubitemid 129702687)
33. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptorpositive tumor cells. Bioconjug Chem 2006; 17: 603-9. (Pubitemid 43794369)
34. Gibson JD, Khanal BP, Zubarev ER. Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc 2007; 129: 11653-61. (Pubitemid 47555582)
35. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor targeted drug delivery. Biomaterials 2009; 30 : 6065-75.
36. Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc 2007; 129: 2669-75. (Pubitemid 46364075)
37. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008; 60: 1278-88.
38. Manzano M, Colilla M, Vallet-Regi M. Drug delivery from ordered mesoporous matrices. Expert Opin Drug Deliv 2009; 6: 1383-400.
39. Giri S, Trewyn BG, Stellmaker MP, Lin VS. Stimuli-responsive controlled release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl 2005; 44: 5038-44. (Pubitemid 41188539)
40. Park JH, Gu L, Von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 2009; 8: 331-6.
41. Jana NR, Earhart C, Ying JY. Synthesis of water-soluble and functionalized nanoparticles by silica coating. Chem Mater 2007; 19 5074-82. (Pubitemid 350014249)
42. Sathe TR, Agrawal A, Nie S. Mesoporous silica beads embedded with semiconductor quantum dots and iron oxide nanocrystals: dual-function microcarriers for optical encoding and magnetic separation. Anal Chem 2006; 78: 5627-32. (Pubitemid 44265020)
43. Koole R, van Schooneveld MM, Hilhorst J, et al. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem 2008; 19: 2471-9.
44. Roy I, Ohulchanskyy Pudavar HE, et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J A m Chem Soc 2003; 125: 7860-5. (Pubitemid 36782161)
45. Svenson S, Tomalia DA. Dendrimers in biomedical applications reflections on the field. Adv Drug Deliv Rev 2005; 57: 2106-29. (Pubitemid 41759389)
46. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem 2006; 17: 275-83.
47. Morgan MT, Carnahan MA, Immoos CE, et al. Dendritic molecular capsules for hydrophobic compounds. J Am Chem Soc 2003; 125: 15485-9. (Pubitemid 37532190)
48. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr., Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007; 14: 107-15. (Pubitemid 46124068)
49. Lee CC, MacKay JA, Frechet Jean MJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005; 23: 1517-26. (Pubitemid 41752929)
50. Kannan, Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of Dendrimer-Methotrexate Conjugates on Methotrexate-Sensitive and -Resistant Cell Lines. Bioconjugate Chem 2006; 17(2): 275-283.
51. Welsher K, Liu Z, Daranciang D, Dai H. Selective probing and imaging of cells with single walled carbon nanotubes as nearinfrared fluorescent molecules. Nano Lett 2008; 8: 586-90. (Pubitemid 351346022)
52. Kam NW, Liu Z, Dai H. Carbon nanotubes as intracellular transporters for Advancement in multifunctional nanoparticles for the effective treatment of cancer proteins and DNA: an investigation of the uptake mechanism and pathway. Angew Chem Int Ed Engl 2006; 45: 577-81. (Pubitemid 43121447)
53. Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006; 12(16): 4933-9 . (Pubitemid 44338581)
54. Moon HK, Lee SH, Choi HC. In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano 2009; 3: 3707-13.
55. Zhang YB, Tan YW, Stormer HL, Kim P. Experimental observation o f the quantum hall effect and Berry's phase in grapheme. Nature 2005; 438: 201-4. (Pubitemid 41599868)
56. Novoselov KS, Jiang Z, Zhang Y, et al. Room-temperature quantum Hall effect in grapheme. Science 2007; 315: 1379. (Pubitemid 46399539)
57. Balandin AA, Ghosh S, Bao W, et al. Superior thermal conductivity o f single-layer grapheme. Nano Lett 2008; 8: 902-7.
58. Lee C, Wei X, Kysar JW, Hone J. Measurement of the elastic properties and intrinsic strength of monolayer grapheme. Science 2008; 321: 385-8. (Pubitemid 352029970)
59. Li X, Wang X, Zhang L, Lee S, Dai H. Chemically derived, ultra smooth graphene nanoribbon semiconductors. Science 2008; 319: 1229.
60. Berger C, Song ZM, Li TB, et al. Ultrathin epitaxial graphite: 2D electron gas properties and a route toward graphene-based nanoelectronics. J Phys Chem B 2004; 108: 19912-6. (Pubitemid 40079151)
61. Marsh D, Bartucci R, Sportelli L. Lipid membranes with grafted polymers: physicochemical aspects. Biochim Biophys Acta 2003; 1615(1-2): 33-59. (Pubitemid 37013466)
62. Risbo J, Jorgensen K, Sperotto MM, Mouritsen OG. Phase behavior and permeability properties of phospholipid bilayers containing a short-chain phospholipid permeability enhancer. Biochim Biophys Acta 1997; 1329(1): 85-96. (Pubitemid 27466065)
63. Mills JK, Needham D. The materials engineering of temperaturesensitive liposomes. Methods Enzymol 2004; 387: 82-113.
64. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature - sensitive liposome for use with mild h yperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60(5) : 1197-201. (Pubitemid 30151982)
65. Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 2005; 1716(2): 77-96. (Pubitemid 41532286)
66. Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 2003; 14(4): 738-47. (Pubitemid 36875433)
67. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002; 54: 715-58. (Pubitemid 35247524)
68. Rolland AP. From genes to gene medicines: recent advances in nonviral gene delivery. Crit Rev Ther Drug Carrier System 1998; 15: 143-98. (Pubitemid 28208750)
69. Collins L, Fabre JW. A synthetic peptide vector system for optimal gene delivery to corneal endothelium. J Gene Med 2004; 6: 185-94. (Pubitemid 40228037)
70. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm 2001; 229: 1-21. (Pubitemid 32972076)
71. Kircheis R, Blessing T, Brunner S, Wightman L, Wagner E. Tumor targeting with surface-shielded ligand-polycation DNA complexes. J Control Release 2001; 72: 165-70. (Pubitemid 32522354)
72. Yang R, Shim WS, Cui F, et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int Jour of Pharm 2009; 371: 2142-7.
73. Yang R, Yang S. Lung-specific delivery of paclitaxel by chitosanmodified PLGA nanoparticles via transient formation of microaggregates. J of Pharm Sci 2009; 98: 970-84.
74. Wang J, Mao HQ, Leong KW. A novel biodegradable gene carrier based on polyphosphoester. J Am Chem Soc 2001; 123: 9480-1. (Pubitemid 32900333)
75. Vergara D, Bellomo C, Zhang X, et al.. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multi drug resistance in ovarian cancer. Nanomedicine 2011 Nov 16. [Epub ahead of print].
76. Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging targeting, and drug delivery. ACS Nano 2008; 25: 889-96.
77. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008; 60 : 1241-51.
78. Lukianova-Hleb EY, Hanna EY, Hafner JH, Lapotko DO. Tunable plasmonic nanobubbles for cell theranostics. Nanotechnology 2010; 21: 85-102.
79. Shim MS, Kim CS, Ahn YC, Chen Z, Kwon YJ. Combined multimodal optical imaging and targeted gene silencing using stimulitransforming nanotheragnostics. J Am Chem Soc 2010; 132: 8316-24.
80. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005; 65: 5317-24. (Pubitemid 40827344)
81. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009; 30: 5737-50.
82. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009; 61: 467-77.
83. Lin YS, Wu SH, Hung Y, et al. Multifunctional composite nanoparticles: magnetic, luminescent, and mesoporous. Chem Mater 2006; 18: 5170-2. (Pubitemid 44759376)
84. Kim JS, Rieter WJ, Taylor KM, An H, Lin W, Lin W. Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J Am Chem Soc 2007; 129: 8962-3. (Pubitemid 47171835)
85. Rieter WJ, Kim JS, Taylor K, et al. Hybrid silica nanoparticles for multimodal imaging. Angew Chem Int Ed 2007; 46: 3680-2. (Pubitemid 46981247)
86. Rieter WJ, Taylor K, An H, Lin W, Lin W. Nanoscale metalorganic frameworks as potential multimodal contrast enhancing agents. J Am Chem Soc 2006; 128: 9024-25. (Pubitemid 44078972)
87. Choi JS, Jun YW, Yeon SI, Kim HC, Shin JS, Cheon J. Biocompatible heterostructured nanoparticles for multimodal biological detection. J Am Chem Soc 2006; 128: 15982-3. (Pubitemid 44936560)
88. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150: 552-8. (Pubitemid 46355555)
89. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2(1): 99-112.
90. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007; 2: 249-55. (Pubitemid 46739812)
91. Derfus AM, Chan WC, Bhatia SN. Probing the cytotoxicity of semi-conductor quantum dots. Nano Lett 2004; 4: 11-8. (Pubitemid 38167855)
92. Soto K, Garza KM, Murr LE. Cytotoxic effects of aggregated nanomaterials. Acta Biomater 2007; 3: 351-58. (Pubitemid 46555129)
93. Soto KF, Carrasco A, Powell TG, Garza KM, Murr LE. Comparative in vitro cytotoxicity assessment of some manufactured nanoparticulate materials characterized by transmission electron microscopy. J Nanopart Res 2005; 7: 145-69. (Pubitemid 40940543)
94. Balbus JM, Maynard AD, Colvin VL, et al. Meeting report: hazard assessment for nanoparticles - report from an interdisciplinary workshop. Environ Health Perspect 2007; 115: 1654-9.
95. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006; 114: 165-72. (Pubitemid 43193634)
96. Nel A, Xia T, Madler L. Toxic potential of materials at the nanolevel. Science 2006; 311: 622-7. (Pubitemid 43191298)
97. Borm P, Klaessig FC, Landry TD, et al. Research strategies for safety evaluation of nanomaterials. Part V. Role of dissolution in biological fate and effects of nanoscale particles. Toxicol 2006; 90: 23-32. (Pubitemid 43264723)
98. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles - potential implications for drug delivery. J Nanosci Nanotech 2004; 4: 521-31. (Pubitemid 39387404)
99. Yamamoto A, Honma R, Sumita M, Hanawa T. Cytotoxicity evaluation of ceramic particles of different sizes and shapes. J Biomed Mater Res 2004; 68: 244-56. (Pubitemid 38524718)
100. Karakoti AS, Hench LL, Seal S, et al. The potential toxicity of nanomaterials - the role of surfaces. J Min Met Mater Soc 2006; 58: 77-82. (Pubitemid 44083655)
101. Yoshida K, Morita M, Mishina H. Cytotoxicity of metal and ceramic particles in different sizes. JSME Int J C Mech Syst 2003; 46: 1284-89. (Pubitemid 38265641)